Medicine and Dentistry
Hepatocellular Carcinoma
100%
Patient
32%
Overall Survival
23%
Inpatient
21%
Chronic Hepatitis B
18%
Liver Cirrhosis
15%
Liver Transplantation
15%
Neoplasm
14%
Transcatheter Arterial Chemoembolization
14%
Vascular Tissue Neoplasm
14%
Hepatic Portal Vein
14%
Tumor Thrombus
14%
Treatment Response
13%
Bevacizumab
13%
Sorafenib
13%
Hepatitis B Antigen
12%
Hepatitis C Virus
12%
Liver Function
12%
Personal Experience
11%
Hepatic Arterial Infusion
11%
Liver Cancer
10%
Therapeutic Procedure
10%
Cancer Staging
9%
Intraarterial Drug Administration
9%
Cohort Analysis
9%
Progression Free Survival
9%
Liver Graft
8%
Lenvatinib
8%
Hazard Ratio
8%
Common Hepatic Artery
8%
Combination Therapy
8%
Hepatitis B Virus
7%
Chemotherapy
7%
Analysis
6%
Fibrosis
6%
Tumor Necrosis Factor
6%
Hepatitis B
6%
Association
6%
Fulminant
5%
Disease Exacerbation
5%
Vasculitis
5%
Long Term Survival
5%
Systemic Lupus Erythematosus
5%
Brain Metastasis
5%
Nonalcoholic Fatty Liver
5%
Ledipasvir Plus Sofosbuvir
5%
Tenofovir Disoproxil
5%
Mammalian Target of Rapamycin Inhibitor
5%
Bone Necrosis
5%
Sarcopenia
5%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
66%
Liver Cell Carcinoma
26%
Overall Survival
18%
Sorafenib
18%
Chronic Hepatitis B
12%
Liver Cirrhosis
11%
Hepatitis C Virus
10%
Bevacizumab
10%
Atezolizumab
10%
Cohort Study
9%
Tumor Thrombus
9%
Vascular Tumor
9%
Nonalcoholic Fatty Liver
8%
Progression Free Survival
8%
Hepatitis B Antigen
8%
Neoplasm
8%
Liver Cancer
6%
Cancer Staging
6%
Chemotherapy
6%
Hepatitis B Virus
6%
Ledipasvir Plus Sofosbuvir
6%
Hepatitis B
6%
Chronic Hepatitis B
5%
Ledipasvir
5%
Tenofovir Alafenamide
5%
Lenvatinib
5%
Sofosbuvir
5%
Tenofovir Disoproxil
5%
Binding Protein
5%
Antiviral Therapy
5%
Antivirus Agent
5%
Immunology and Microbiology
Hepatitis B Virus
14%
Immunity
10%
Hepatitis B Virus
10%
Overall Survival
10%
Hepatitis B
9%
Atezolizumab
8%
Bevacizumab
8%
HBsAg
8%
Hepatitis B
6%
Immunosuppressive Therapy
5%
Gene Mutation
5%
Telomere Length
5%
Reverse Transcriptase
5%
Cytotoxic T-Cell
5%
Protein Glycosylation
5%
Protein Binding
5%
Progression Free Survival
5%